Pioglitazone, but not gliclazide or metformin, improves the adipokine profile of overweight type 2 diabetes patients independent of glycaemic control
Reference:
Reid, J., Lawrence, J. M., Taylor, G. J., Stirling, C. A. and Reckless, J. P. D., 2006. Pioglitazone, but not gliclazide or metformin, improves the adipokine profile of overweight type 2 diabetes patients independent of glycaemic control. Atherosclerosis Supplements, 7 (3), p. 330.
Related documents:
This repository does not currently have the full-text of this item.You may be able to access a copy if URLs are provided below.
Details
| Item Type | Articles |
| Creators | Reid, J., Lawrence, J. M., Taylor, G. J., Stirling, C. A. and Reckless, J. P. D. |
| Departments | Faculty of Humanities & Social Sciences > Health |
| Refereed | Yes |
| Status | Published |
| ID Code | 6396 |
| Additional Information | ID number: ISI:000239093902096 |
Export
Actions (login required)
| View Item |
